Search Results

CSL KMP in 2024 AGM Annual General Meeting Name Position Term as KMP ARMC Audit and Risk Management Committee CEO Chief Executive Officer and Managing Director NEDs CFO Cashflow from Operations Dr Brian Chair and Independent Full year McNamee AO Non-Executive Director EPS Earnings per Share Dr Megan Independent Full year EPSg Earnings per Share growth Clark AC Non-Executive Director EVP Executive Vice President Professor Andrew Non-Independent Full year Cuthbertson AO Non-Executive Director FR Fixed Reward Ms Carolyn Independent Full year HRRC Human Resources and Remuneration Hewson AO Non-Executive Director Committee Ms Independent Part year - from KMP Key Management Personnel Samantha Lewis Non-Executive Director 1 January 2024 KPI Key Performance Indicator Professor Independent Full year LTI Long Term Incentive Duncan Maskell Non-Executive Director NED Non-Executive Director Ms Marie Independent Full year McDonald Non-Executive Director NPATA Net Profit after Tax and before Amortisation1 Ms Alison Independent Full year PSU Performance Share Unit Watkins AM Non-Executive Director

CSL was originally established by the Australian government in As at 30 June 2021, the CSL Group employed over 25,000 full 1916 for the purpose of supplying Australia with vaccines and time equivalents (FTE) and delivered medicines to patients other bacteriological products.

In fiscal year 2021-2022, CSL invested approximately $1.16 billion in R&D.

The full year fixed reward for P Perreault was US$1,856,133, the full year cash STI payment was US$2,262,385 and the full year share based payment expense was US$3,654,625.

CSL’s vision is a sustainable future for our employees, communities, patients and donors, inspired by innovative science and a values-driven culture.

CSL's Code of Responsible Business Practices guides our interactions with stakeholders and sets expectations for responsible business conduct.

N Engl J Med 2021

CSL engages stakeholders and periodically undertakes a formal materiality assessment process to understand our relevant sustainability-related topics.

About the PI Survey The survey was conducted on behalf of CSL Behring between August 4 and September 22, 2021, among 104 PI patients that have ever received immune globulin treatment, including IVIg (n=65), SCIg in glass vials (n=65), and/or SCIg in PFS (n=33).

This of its full year results, with the in the United States which will support CSL's growing R&D appointment highlights CSL's briefing materials released to portfolio including the next-generation mRNA technology long-term commitment to the ASX on 15 August 2023.